Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification

Authors

M N. Sabbagh, Marwan Noel Sabbagh MD, FAAN, c/o Neuroscience Publications; Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ 85013; Tel: 602.406.3593; Fax: 602.406.4104; E-mail: Neuropub@barrowneuro.org.

Document Type

Article

Medical Subject Headings

Alzheimer Disease (drug therapy, genetics); Apolipoprotein E4 (genetics); GABA Agonists (therapeutic use); Homozygote; Humans; Taurine (analogs & derivatives, therapeutic use)

Publication Date

2017

Publication Title

The journal of prevention of Alzheimer's disease

E-ISSN

2426-0266

Volume

4

Issue

3

First Page

136

Last Page

137

PubMed ID

29182703

Digital Object Identifier (DOI)

10.14283/jpad.2017.24

Recommended Citation

Sabbagh, M N., "Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification" (2017). Neurology. 811.
https://scholar.barrowneuro.org/neurology/811